Aradigm Corporation secures USD260,000 NIH grant to investigate new diagnoses tests of aspirations of gastrointestinal contents into respiratory tract.
M2 EQUITYBITES-August 12, 2013-Aradigm Corporation secures USD260,000 NIH grant to investigate new diagnoses tests of aspirations of gastrointestinal contents into respiratory tract(C)2013 M2 COMMUNICATIONS http://www.m2.com
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM) revealed on Friday the receipt of a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into the respiratory tract.
This USD260,000 grant was awarded by The National Heart, Lung, and Blood Institute, National Institutes of Health (NIH).
The company added that the principal investigators and co-inventors of the new diagnostic tests are Professor Homer Boushey, University of California, San Francisco (UCSF) and Dr Igor Gonda, Aradigm Corporation.
According to the company, the grant will fund the laboratory work and a human clinical trial to be conducted at UCSF.
Aspiration of gastric contents into the respiratory tract reportedly causes significant morbidity and mortality and is accepted as the key initiating event for aspiration pneumonitis - a form of acute lung injury caused by the acidity of the gastric contents, and aspiration pneumonia - the consequence of the growth of pathogenic bacteria contained in the oropharynx aspirated into the tracheobronchial tree. When subclinical events of gastric aspiration occur, it is described as "silent aspiration" or "microaspiration."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 12, 2013|
|Previous Article:||Walmart's Massmart eyes deals in Kenya.|
|Next Article:||Actavis Inc awarded French Competition Authority's approval to acquire Warner Chilcott plc for undisclosed fee.|